76 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
and expenses of the nature referred to in Item 14 of Part II of the Registration Statement. Except as provided in this Section 4 or in Section 7
424B5
TRML
Tourmaline Bio Inc
26 Jan 24
Prospectus supplement for primary offering
4:08pm
that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended
424B5
TRML
Tourmaline Bio Inc
24 Jan 24
Prospectus supplement for primary offering
9:20pm
that are not strictly historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended
8-K
EX-99.3
dkjd74p b30avn03ss6
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
199dwyrswo5
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.2
ceg21
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
gkgxdbm89 mv2
14 Nov 23
Index to Unaudited Condensed Financial Statements
5:15pm
8-K
EX-10.10
2dw8rqs9c
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.9
h8a im8m6sp34j6jnx8
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
8-K
EX-10.7
4co alsdhf
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
wtqjaops1mwyd2v8ur
10 Oct 23
Business combination disclosure
4:32pm
8-K/A
yaya hzijrs8xvhk
10 Oct 23
Other Events
4:30pm
425
ieyrl z4p2
6 Oct 23
Business combination disclosure
5:27pm
8-K
07tg95 52803i
6 Oct 23
Other Events
5:26pm
425
7us6cv18su8 vx480p9j
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
g98y7gp8cwualhskti
26 Sep 23
Regulation FD Disclosure
8:21am
8-K
dct dkp14kou
26 Sep 23
Regulation FD Disclosure
8:21am